Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults

Abstract

BACKGROUND: A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous regimen using HIV-1 subtype C virus showed potent humoral and cellular responses in a phase 1-2a trial in South Africa. Efficacy data and additional safety data were needed for this regimen in a larger population in South Africa. METHODS: In this phase 2b-3 trial, we randomly assigned 5404 adults without HIV-1 infection to receive the vaccine (2704 participants) or placebo (2700 participants). The vaccine regimen consisted of injections of ALVAC-HIV at months 0 and 1, followed by four booster injections of ALVAC-HIV plus bivalent subtype C gp120-MF59 adjuvant at months 3, 6, 12, and 18. The primary efficacy outcome was the occurrence of HIV-1 infection from randomization to 24 months. RESULTS: In January 2020, prespecified criteria for nonefficacy were met at an interim analysis; further vaccinations were subsequently halted. The median age of the trial participants was 24 years; 70% of the participants were women. The incidence of adverse events was similar in the vaccine and placebo groups. During the 24-month follow-up, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P = 0.84). CONCLUSIONS: The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity. (HVTN 702 ClinicalTrials.gov number, NCT02968849.).

Shown for reading. Its publisher allows quoting it, not republishing it.

References 27

1. 1.

   UNAIDS. UNAIDS Fact Sheet 2018. Geneva, Switzerland 2018.

   Not in our library

2. 2.

   Human Sciences Research Council. The Fifth South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017: HIV Impact Assessment Summary Report. Cape Town, South Africa 2018.

   Not in our library

3. 3.

   Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.

   Not in our library10.1056/nejmoa0908492

4. 4.

   Gray G, Doherty T, Mohapi L, et al. HIV research in South Africa: Advancing life. South African Medical Journal 2019;109:36-40.

   Not in our library10.7196/samj.2019.v109i11b.14264

5. 5.

   Laher F, Moodie Z, Cohen KW, et al. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med 2020;17:e1003038.

   Not in our library10.1371/journal.pmed.1003038

6. 6.

   Gilbert PB, Grove D, Gabriel E, et al. A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Stat Commun Infect Dis 2011;3.

   Not in our library10.2202/1948-4690.1037

7. 7.

   Holm S. A Simple Sequentially Rejective Multiple Test Procedure. Scandinavian Journal of Statistics 1979;6:65-70.

   Not in our library

8. 8.

   O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007;6:699-710.

   Not in our library10.1586/14760584.6.5.699

9. 9.

   O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012;30:4341-8.

   Not in our library10.1016/j.vaccine.2011.09.061

10. 10.

    Shen X, Laher F, Moodie Z, et al. HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. Sci Rep 2020;10:2093.

    Not in our library10.1038/s41598-020-57491-z

11. 11.

    Bekker LG, Moodie Z, Grunenberg N, et al. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV 2018;5:e366-e78.

    Not in our library10.1016/s2352-3018(18)30071-7

12. 12.
    Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial · 2013

    No notice
13. 13.

    Gray GE, Huang Y, Grunenberg N, et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med 2019;11.

    Not in our library10.1126/scitranslmed.aax1880

14. 14.

    Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-86.

    Not in our library10.1056/nejmoa1113425

15. 15.

    Passmore JA, Jaspan HB, Masson L. Genital inflammation, immune activation and risk of sexual HIV acquisition. Curr Opin HIV AIDS 2016;11:156-62.

    Not in our library10.1097/coh.0000000000000232

16. 16.

    Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011;378:256-68.

    Not in our library10.1016/s0140-6736(11)60842-8

17. 17.

    Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012;12:531-7.

    Not in our library10.1016/s1473-3099(12)70088-9

18. 18.

    Vaccari M, Keele BF, Bosinger SE, et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol 2013;87:3538-48.

    Not in our library10.1128/jvi.02863-12

19. 19.

    Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012;490:417-20.

    Not in our library10.1038/nature11519

20. 20.

    Rademeyer C, Korber B, Seaman MS, et al. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog 2016;12:e1005742.

    Not in our library10.1371/journal.ppat.1005742

21. 21.

    Los Alamos National Labs (Accessed September 28, 2020, at http://www.hiv.lanl.gov/.)

    Not in our library

22. 22.

    Li SS, Gilbert PB, Tomaras GD, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest 2014;124:3879-90.

    Not in our library10.1172/jci75539

23. 23.

    Gartland AJ, Li S, McNevin J, et al. Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. J Virol 2014;88:8242-55.

    Not in our library10.1128/jvi.01164-14

24. 24.

    Prentice HA, Tomaras GD, Geraghty DE, et al. HLA class II genes modulate vaccineinduced antibody responses to affect HIV-1 acquisition. Sci Transl Med 2015;7:296ra112.

    Not in our library10.1126/scitranslmed.aab4005

25. 25.

    Lassauniere R, Tiemessen CT. Variability at the FCGR locus: characterization in Black South Africans and evidence for ethnic variation in and out of Africa. Genes Immun 2016;17:93104.

    Not in our library10.1038/gene.2015.60

26. 26.

    Hertz T, Logan MG, Rolland M, et al. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. Vaccine 2016;34:5792-801.

    Not in our library10.1016/j.vaccine.2016.09.054

27. 27.

    Tshabalala M, Mellet J, Pepper MS. Human Leukocyte Antigen Diversity: A Southern African Perspective. J Immunol Res 2015;2015:746151.

    Not in our library10.1155/2015/746151

Cited by papers we hold 4

• Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases · 2023
  No notice
• Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s · 2022
  Not checked
• Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial · 2022
  Corrected
• The use of viral vectors in vaccine development · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.